This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Takeyama, H. Articles by Ohno, T. Search for Related Content PubMed PubMed Citation Articles by Takeyama, H. Articles by Ohno, T.

Production of a Novel Monoclonal Antibody, JT-95, Which Can Detect Antigen of Thyroid Carcinoma

First Departments of Surgery [H. T., T. H., K. S.], Radiology [Y. M.], and Microbiology [M. W., H. K., T. O.] and Department of Oncology, Institute of DNA Medicine [T. O.], Jikei University School of Medicine, 3-25-8 Nishi-shinbasi, Minato-ku, Tokyo 105, Japan

Monoclonal antibody (MAb) JT-95 was produced by immunization of mice with membrane fractions of a human thyroid carcinoma. Immunohistochemical staining has demonstrated that the antigen recognized by JT-95 is strongly expressed in 95 (95%) of 100 cases of papillary carcinomas and in 3 (75%) of 4 cases of follicular carcinomas. In benign diseases of the thyroid gland, MAb JT-95 reacted with 0 (0%) of 39 adenomas, 1 (4%) of 21 adenomatous goiters, 0 (0%) of 8 hyperthyroidism specimens, and 3 (38%) of 8 chronic thyroiditis specimens. The antigen detected by MAb JT-95 has an apparent M_r 250,000 in thyroid carcinomas. Moreover, circulating antigen in thyroid carcinoma patients was detected using MAb JT-95 in an ELISA and in Western blotting. The circulating antigen has a M_r 105,000. MAb JT-95 conjugated with ¹³¹I was administrated to nude mice bearing a human thyroid carcinoma. JT-95-¹³¹I accumulation at the transplanted tumor was visualized by autoradiography with 2.68–14.75-fold higher levels detected at the xenograft compared to that for normal organs. Based on these data, MAb JT-95 may be useful in the diagnosis detection and therapy of thyroid carcinoma.

¹ To whom requests for reprints should be addressed.

Received 5/ 8/95. Accepted 2/ 8/96.